Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Chinese University of Hong Kong |
---|---|
Information provided by: | Chinese University of Hong Kong |
ClinicalTrials.gov Identifier: | NCT00286104 |
External ventricular catheters are used for intracranial pressure monitoring and temporary cerebrospinal fluid (CSF) drainage in neurosurgery. The incidence of ventriculostomy-related cerebrospinal fluid infections had been quoted as between 2.2% to 10.4% in the more recent literature. Previous prospective studies in the investigators' unit have shown that the use of dual antibiotics prophylaxis in patients with external ventricular drain was associated with decreased incidence of CSF infection but was complicated with opportunistic extracranial infections. The current practice is to cover with prophylactic dual antibiotics unless guided by microbiology results for all patients with external ventricular drain. In recent years, cerebrospinal fluid shunt catheters impregnated with antimicrobial agents have been available. Experimental studies have shown that they provide protection against staphylococcal aureus and coagulase-negative staphylococci strains for between 42 days and 56 days. Theoretically, they provide the antibiotic prophylaxis locally without the associated complications of systemic antibiotics.
It is hypothesized that the use of antibiotic-impregnated catheters instead of systemic antibiotic prophylaxis will not increase the rate of cerebrospinal fluid infection, will decrease the rate of opportunistic/nosocomial infections and improves the overall outcome in these patients; that would convert into a reduction in treatment cost of these patients.
Condition | Intervention | Phase |
---|---|---|
Hydrocephalus Intracranial Hypertension |
Device: Antibiotics-impregnated ventricular catheter (Bactiseal®) Device: Plain ventricular catheter (Codman EDS II/III) |
Phase III |
Study Type: | Interventional |
Study Design: | Prevention, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study |
Official Title: | The Impact of Ventricular Catheter Impregnated With Antimicrobial Agents on Infection in Patients With Ventricular Catheter: A Prospective Randomized Study |
Estimated Enrollment: | 180 |
Study Start Date: | April 2004 |
Estimated Study Completion Date: | October 2009 |
Estimated Primary Completion Date: | March 2009 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Active Comparator
Bactiseal ventricular catheter (Rifampicin- and Clindamycin-impregnated)
|
Device: Antibiotics-impregnated ventricular catheter (Bactiseal®)
Antibiotics-impregnated ventricular catheter (Rifampicin- and Clindamycin-impregnated)
|
2: Placebo Comparator
Plain ventricular catheter
|
Device: Plain ventricular catheter (Codman EDS II/III)
Plain ventricular catheter
|
Objective:
Design: Prospective randomized controlled trial
Hypothesis: The use of antibiotics-impregnated catheter instead of systemic antibiotic prophylaxis will not increase the rate of cerebrospinal fluid infection, will decrease the rate of opportunistic/nosocomial infection and improves the overall outcome in these patients; that would convert into a reduction in treatment cost of these patients.
Method: After ventricular catheter insertion, patients will be randomized into one of the two groups:
Primary outcome variable: Cerebrospinal fluid infection and extracranial infection.
Sample size: We aim to recruit a total of 180 patients with 90 patients in each arm and expect to complete patient recruitment in 2-3 years. The calculation is based to detect a difference of nosocomial infection rate between 20% and 40%, with 5% level of significance and 80% power.
Projected results and significance:
The project has a good chance to be the first clinical study to the outcome and cost impacts of antibiotic-impregnated ventricular catheter.
Ages Eligible for Study: | 18 Years to 80 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: George KC Wong, FRCSEd(SN) | +852 2632 2624 | georgewong@surgery.cuhk.edu.hk |
Contact: Wai S Poon, FRCS | +852 2632 2638 | wpoon@surgery.cuhk.edu.hk |
China | |
Division of Neurosurgery, Prince of Wales Hospital, Chinese University of Hong Kong | Recruiting |
Hong Kong, China, 852 | |
Contact: George KC Wong 852 26322624 | |
Sub-Investigator: Wai S Poon, FRCS | |
Principal Investigator: George KC Wong, FRCSEd(SN) | |
Sub-Investigator: Margaret Ip, FRCPA |
Principal Investigator: | George KC Wong, FRCSEd(SN) | Chinese University of Hong Kong |
Study Director: | George KC Wong, FRCSEd(SN) | Chinese University of Hong Kong |
Responsible Party: | Division of Neurosurgery, The Chinese University of Hong Kong ( George KC Wong ) |
Study ID Numbers: | CREC-PWS-002 |
Study First Received: | February 1, 2006 |
Last Updated: | July 31, 2008 |
ClinicalTrials.gov Identifier: | NCT00286104 History of Changes |
Health Authority: | Hong Kong: Department of Health |
Ventriculitis External ventricular catheter Antibiotic-impregnated |
Rifampin Anti-Bacterial Agents Clindamycin Clindamycin-2-phosphate Vascular Diseases Pseudotumor Cerebri |
Infant, Newborn, Diseases Central Nervous System Diseases Hydrocephalus Brain Diseases Intracranial Hypertension Hypertension |
Anti-Infective Agents Nervous System Diseases Pseudotumor Cerebri Vascular Diseases Central Nervous System Diseases Brain Diseases Pharmacologic Actions |
Intracranial Hypertension Anti-Bacterial Agents Therapeutic Uses Infant, Newborn, Diseases Cardiovascular Diseases Hydrocephalus Hypertension |